Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Balance Sheet

v3.21.1
Condensed Consolidated Interim Balance Sheet - USD ($)
$ in Thousands
Mar. 31, 2021
Jun. 30, 2020
Current assets    
Cash and cash equivalents $ 15,718 $ 2,392
Prepaid expenses and deposits 363 356
Clinical trial deposit 500  
Interest, taxes and other receivables 7 9
Deferred loan costs   94
Current assets 16,588 2,851
Clinical trial deposit 2,100  
Intangible assets - net   2
Property and equipment - net 165  
Deferred financing costs   85
Total assets 18,853 2,938
Current liabilities    
Accounts payable and accrued liabilities 1,645 2,011
Loan payable, net of deferred loan costs 503  
Related party payables 385 664
Current liabilities 2,533 2,675
Milestone payment liability 202  
Total liabilities 2,735 2,675
Stockholders’ equity    
Common stock Authorized 95,000 shares at March 31, 2021 and June 30, 2020, $0.001 par value 31,764 issued at March 31, 2021 (June 30, 2020 - 11,458) 32 11
Additional paid-in capital 100,828 65,148
Accumulated deficit (104,489) (69,721)
Accumulated other comprehensive income 21 21
Total stockholders’ equity 16,118 263
Total liabilities and stockholders’ equity 18,853 2,938
Preferred Stock Series A    
Stockholders’ equity    
Preferred stock 279 279
Preferred Stock Series B    
Stockholders’ equity    
Preferred stock 4,196 4,525
Total stockholders’ equity 4,196 $ 4,525
Preferred Stock Series C    
Stockholders’ equity    
Preferred stock $ 15,251